Cogent Biosciences filed a new drug application (NDA) for bezuclastinib in patients with gastrointestinal stromal tumors (GIST) who have progressed on imatinib on April 1 2026. The submission follows the Phase 3 PEAK trial, which demonstrated a 50% reduction in the risk of disease progression or death (hazard ratio 0.50, 95% CI 0.39–0.65) and a 46% objective response rate versus 26% for sunitinib alone. Median progression‑free survival was 16.5 months for the bezuclastinib combination compared with 9.2 months for sunitinib monotherapy.
Cogent’s president and chief executive officer, Andrew Robbins, said regarding the GIST NDA submission under RTOR: "This milestone reflects the FDA's recognition of the significant unmet need facing patients with imatinib resistant GIST. Based on positive results from the PEAK trial, the bezuclastinib combination has the potential to be the first new approval in this patient population in over 20 years. We look forward to the continued, close collaboration with the FDA as we advance bezuclastinib toward commercialization."
Regarding the Breakthrough Therapy Designation for GIST, Robbins also said: "We are excited to announce this Breakthrough Therapy Designation which recognizes the potential for the bezuclastinib combination to substantially improve upon the currently available treatment options for patients with imatinib-resistant GIST. We look forward to the continued collaboration with the FDA as we work to bring the first new treatment option in over twenty years to this patient population."
In a press release from November 10 2025, Neeta Somaiah, MD, professor and department chair, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, commented on the PEAK trial results: "The results from the PEAK trial are truly transformative and practice changing. Following regulatory approval, I expect the bezuclastinib combination to be rapidly adopted as the new standard of care treatment for the majority of patients in the second‑line GIST setting."
Cogent is leveraging the FDA’s Real‑Time Oncology Review (RTOR) program to accelerate the review process, a move that could shorten the time to market for a therapy that would be the first new second‑line option for GIST in more than two decades. The company’s strong cash position—$900.8 million in cash, cash equivalents, and marketable securities as of December 31 2025—provides a runway through 2028, allowing continued investment in clinical development and potential commercialization activities.
Financially, Cogent reported a net loss of $102.5 million for Q4 2025 and $328.9 million for the full year 2025, compared with a net loss of $67.9 million for Q4 2024 and $255.9 million for the full year 2024. Research and development expenses were $75.6 million for Q4 2025 and $269.8 million for the full year 2025, reflecting the company’s focus on advancing bezuclastinib and other programs.
Investor sentiment has been mixed; while the regulatory milestone is positive, insider selling by top executives has tempered enthusiasm. Analyst consensus remains generally positive, with a moderate buy outlook and expectations that the drug could become the new standard of care in the second‑line GIST setting.
The NDA submission, backed by robust clinical data and expedited review pathways, positions Cogent to potentially fill a critical unmet need in a rare cancer market, while its financial footing supports continued development and eventual commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.